Weight regain after discontinuation: difference between revisions
Diff·revision 1 → 2·04:53, 14 Sep 2024
Difference between revision 1 and revision 2 of Weight regain after discontinuation. 5 lines changed; the page grew by 613 bytes.
| Revision 1 — 09:10, 5 Sep 2024 StopperingSteff (talk) new article: adverse effects, expansion welcome 1,201 bytes +1,201 | Revision 2 — 04:53, 14 Sep 2024 LeanMassLars (talk) expand §Interpretation 1,814 bytes +613 | ||
|---|---|---|---|
| 10 | In [[STEP trial programme|STEP 4]], participants who had reached the maintenance dose during a 20-week run-in were randomised to continue or to switch to placebo. Those continuing lost further weight; those switched regained steadily over the following 48 weeks.{{r|rubino2021}} | 10 | In [[STEP trial programme|STEP 4]], participants who had reached the maintenance dose during a 20-week run-in were randomised to continue or to switch to placebo. Those continuing lost further weight; those switched regained steadily over the following 48 weeks.{{r|rubino2021}} |
| 11 | 11 | ||
| + | 12 | == What the withdrawal trials show == | |
| + | 13 | A randomised withdrawal design is necessary because an observational comparison of people who stop with people who continue is confounded: those who stop differ systematically, often having stopped because of intolerance or lack of response.{{r|rubino2021}} | |
| + | 14 | ||
| + | 15 | STEP 4 and SURMOUNT-4 both randomised after a lead-in on active treatment, so both groups had already lost weight and differed only in what followed. Regain in the withdrawn groups was substantial and progressive; neither trial ran long enough to establish whether weight returns fully to baseline.{{r|rubino2021}} | |
| + | 16 | ||
| 12 | == References == | 17 | == References == |
| 13 | {{reflist}} | 18 | {{reflist}} |